Electronic paramagnetic resonance analysis of point defects in lithium niobate: progress and prospects
Materials Advances · 2025 · 6 (19) · 6648-6663
DOI: 10.1039/d5ma00721f ↗Kurz gefasst
Fachartikel in der Zeitschrift Materials Advances, 2025. Verfasst von Huaize Qin und 9 weiteren Autor:innen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: National Natural Science Foundation of China, Key Technology Research and Development Program of Shandong Province, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Electron paramagnetic resonance (EPR) spectroscopy stands out as a powerful tool for defect characterization in LiNbO 3 crystals, providing unique insights into the formation and local structure of point defects.
Förderung
- National Natural Science Foundation of China
- Key Technology Research and Development Program of Shandong Province
- Natural Science Foundation of Shandong Province
- State Key Laboratory of Crystal Materials
Zitieren
APA
Qin, H., Chen, X., Zhang, J., Song, Y., Zhang, L., Liu, Q., Wang, F., Wang, D., Sang, Y., & Liu, H. (2025). Electronic paramagnetic resonance analysis of point defects in lithium niobate: progress and prospects. Materials Advances, 6(19), 6648-6663. https://doi.org/10.1039/d5ma00721f
Vancouver
Qin H, Chen X, Zhang J, Song Y, Zhang L, Liu Q, et al. Electronic paramagnetic resonance analysis of point defects in lithium niobate: progress and prospects. Materials Advances. 2025;6(19):6648-6663. doi:10.1039/d5ma00721f
BibTeX
@article{Qin2025,
author = {Qin, Huaize and Chen, Xu and Zhang, Jiankang and Song, Yukun and Zhang, Longxi and Liu, Qilu and Wang, Fulei and Wang, Dongzhou and Sang, Yuanhua and Liu, Hong},
title = {Electronic paramagnetic resonance analysis of point defects in lithium niobate: progress and prospects},
journal = {Materials Advances},
year = {2025},
volume = {6},
number = {19},
pages = {6648--6663},
doi = {10.1039/d5ma00721f}
}
EUVIMED